VHCP Management II, LLC

Q4 2019 13F Holdings

  • Location
    new york, NY
  • Num holdings

    20

  • Value ($000)

    $379,352

  • Date Filed
    02/13/2020
  • Form type
    13F-HR
  • CIK
    0001602263
  • All SEC filings
  • Note
    Holdings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q4 2019 to
Select Quarter
Issuer Name
Class
CUSIP
VALUE
%
Shares
Principal
Option Type
TXG
TXG

10X Genomics Inc.

COM
88025U109
$136.22M
36 %

1,786,431

AXSM
AXSM

Axsome Therapeutics Inc

COM
05464T104
$81.24M
21 %

785,981

CNST
CNST

Constellation Pharmaceuticals

COM
210373106
$70.69M
19 %

1,500,631

---

Biohaven Pharmaceuticals

COM
G11196105
$25.20M
7 %

462,903

SWAV
SWAV

Shockwave Medical Inc

COM
82489T104
$12.69M
3 %

288,838

ISEE
ISEE

Iveric Bio Inc

COM
46583P102
$8.62M
2 %

1,004,299

KALV
KALV

Kalvista Pharmaceuticals

COM
483497103
$6.52M
2 %

366,268

---

Obseva SA

COM
H5861P103
$6.01M
2 %

1,573,639

MRSN
MRSN

Mersana Therapeutics Inc

COM
59045L106
$5.29M
1 %

922,514

SPRO
SPRO

Spero Therapeutics Inc

COM
84833T103
$4.56M
1 %

474,015

Rows Per Page
10
  • 10
  • 50
  • 100
1 - 10 of 20